Platinum Industries Limited has informed the Exchange about Incorporation of Subsidiary.
PLATIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Platinum Industries has incorporated a new wholly owned subsidiary named Rivadu Lifesciences Private Limited on March 18, 2026, with CIN U21000MH2026PTC469557. The new subsidiary will operate in the pharma and lifesciences sector, covering a wide range of activities including manufacture and sale of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, excipients, specialty chemicals, finished formulations (tablets, capsules, injectables), biologics, biosimilars, vaccines, nutraceuticals and herbal products. Platinum has subscribed to 100% of the initial paid-up share capital of Rs. 25 lakh (2,50,000 equity shares of Rs. 10 face value) entirely in cash. This follows an earlier intimation to the stock exchanges on February 12, 2026 about the planned subsidiary.
This marks a strategic diversification move by Platinum Industries into the high-growth pharmaceutical and lifesciences space, which could be viewed positively by shareholders as a long-term value creation opportunity. However, the initial capital deployment is small (Rs. 25 lakh), so immediate impact on financials will be limited; the real story will depend on future funding and execution of this new venture.